Article

Pfizer, MediVas team for ophthalmic drug delivery

New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.

New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.

The deal centers on MediVas' fully biodegradable and biocompatible polymers in combination with Pfizer's ophthalmic compounds to increase therapy adherence and improve eye treatments.

MediVas is based in San Diego. Financial terms were not disclosed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.